Published on 23/12/2025
How Phase 4 Studies Support Expanded Access and Compassionate Use Programs
Introduction
Some patients face life-threatening or debilitating diseases for which no approved therapies exist—or they may not qualify for clinical trials. For such cases, Expanded Access (EA) or Compassionate Use (CU) programs offer a regulated pathway to provide investigational treatments outside of traditional research protocols. Phase 4 clinical trials can play a vital supporting role by collecting additional real-world data, validating early efficacy signals, and enhancing the ethical and logistical foundations of these access initiatives.
This guide explains how EA/CU programs operate, how Phase 4 studies contribute to their success, and how to design integrated access models that are compliant, patient-centric, and scientifically robust.
Definitions
Expanded Access (U.S.)
A regulatory mechanism under the U.S. FDA that allows patients with serious or life-threatening conditions to gain access to investigational drugs outside of clinical trials.
Compassionate Use (EU/Global)
Similar to EA, used in the EU and other jurisdictions to describe pre-approval access to investigational therapies for patients with unmet medical needs.
Why Integrate Phase 4 with EA/CU Programs?
- Post-approval support: Some drugs may get accelerated approval with ongoing Phase 4 requirements
- Real-world data generation: Safety and use data from expanded
Eligibility Criteria for EA/CU Programs
- Serious or life-threatening illness
- No comparable or satisfactory alternative therapy
- Patient is not eligible for a clinical trial
- Benefit-risk assessment favors access
- Manufacturer agrees to provide the drug
Types of EA/CU Programs
1. Single-Patient IND (U.S.)
- Physician submits a request for one patient via FDA Form 3926
2. Intermediate-Size EA Protocol
- For small groups, often during transition to full marketing approval
3. Treatment IND / Treatment Protocol
- Broad access during late-phase trials or pending marketing application
4. Cohort Compassionate Use Programs (EU)
- National authorities coordinate access and safety data collection
Regulatory Frameworks
FDA (U.S.)
- 21 CFR Part 312 Subpart I outlines EA mechanisms
- IRB review required for all EA protocols
EMA / National EU Agencies
- Guidance provided under Article 83 of Regulation (EC) No 726/2004
- Each country has its own application and pharmacovigilance requirements
CDSCO (India)
- Permits compassionate use through special import permits under NDCT Rules
- Ethics Committee clearance required
How Phase 4 Trials Complement EA/CU Programs
- Concurrent Data Collection: Safety and use patterns tracked through Phase 4 registries
- Label Expansion: EA experience may inform future formal indications
- Bridging Real-World Evidence: Facilitates regulatory reassessment and HTA reviews
- Supports Health Equity: Provides access to underserved or remote populations
Case Study: Zolgensma in Spinal Muscular Atrophy (SMA)
Zolgensma, a gene therapy for SMA, was initially made available through a global Managed Access Program (MAP). Simultaneously, a Phase 4 registry collected long-term safety and survival data. This dual approach provided regulators with real-world insights and allowed earlier access for hundreds of infants worldwide.
Ethical Considerations
- Informed consent must clearly explain non-standard nature of treatment
- Transparency in data usage for research or regulatory submissions
- Avoid conflict of interest or misrepresentation of outcomes
- Fair patient selection criteria to prevent bias or misuse
Operational Considerations
- Supply chain logistics for pre-approval medications
- Global regulatory variability in program approvals
- Cost coverage and manufacturer reimbursement policies
- Data management integration with PV and RWE platforms
Best Practices for Sponsors
- Align EA/CU design with ongoing Phase 4 protocols
- Predefine key safety endpoints and standardized case report forms
- Collaborate with regulators and patient advocacy groups early
- Use global access partners to scale MAPs effectively
Conclusion
Expanded Access and Compassionate Use programs offer a lifeline to patients in urgent need. When integrated with Phase 4 clinical trial strategies, they become powerful tools for ethical access, scientific validation, and global public health impact. At ClinicalStudies.in, we help sponsors design harmonized EA/Phase 4 programs that comply with global regulations while generating valuable real-world data.